abmart-banner
Global R&D Pipeline
My Favorite
Hot Targets:
Home>AbMart>

Global R&D Pipeline

GD2
Back
Total number of drugs
92
Phase II and later clinical stages
7.6%
Involving companies
87
Main therapeutic areas
Neoplasms
Data Table
Data Chart
Select Row
Fixed Column
Download Table
Molecule Info
R&D and Market Info
ADC Info
DrugDrug Name EnDrug TypeTreatment FieldMechanism of ActionOriginatorDeveloperIndicationHighest Development StageHighest Development Stage (China)Approved Countries/RegionsApproved TimeApproved Time (China)Special ReviewADC TypeADC LinkerADC PayloadADC DARDrug NameAntibody TypeADC Linking SiteOperation
D2-targeting CAR program (Hrain Biotechnology)D2-targeting CAR program (Hrain Biotechnology)Cell therapyDisialoganglioside GD2 modulatorsHrain Biotechnology Co., Ltd.Hrain Biotechnology Co., Ltd.DiscoveryDiscoveryD2-targeting CAR program (Hrain Biotechnology)
detail  >
OGD-201OGD-201Monoclonal antibodyNeoplasms Other DiseasesDisialoganglioside GD2 inhibitorsOGD2 Pharma SASOGD2 Pharma SASPreclinicalOGD-201
detail  >
OGD-203OGD-203CAR-TNeoplasms Nervous System Diseases Other DiseasesDisialoganglioside GD2 inhibitorsOGD2 Pharma SASOGD2 Pharma SASPreclinicalOGD-203
detail  >
Qβ-9NHAc-GD2Qβ-9NHAc-GD2Recombinant vector vaccine Therapeutic vaccineNeoplasmsDisialoganglioside GD2 modulatorsShandong UniversityIaso Therapeutics, Inc.Michigan State UniversityShandong UniversityIaso Therapeutics, Inc.Michigan State UniversityPreclinicalPreclinicalQβ-9NHAc-GD2
detail  >
TB-302TB-302CAR-NK Induced pluripotent stem cells (iPSC)Neoplasms Nervous System Diseases Other DiseasesDisialoganglioside GD2 inhibitorsTherabest, INC.ViGenCell, Inc.Therabest, INC.PreclinicalTB-302
detail  >
CN118416062CN118416062Monoclonal antibodyNeoplasms Other DiseasesTianjin Medical University Cancer Institute and HospitalTianjin Medical University Cancer Institute and HospitalDiscoveryCN118416062
detail  >
WO2023205646WO2023205646CAR-TNeoplasmsWisconsin Alumni Research FoundationWisconsin Alumni Research FoundationDiscoveryWO2023205646
detail  >
Anti-GD2 chimeric antigen receptor T cell therapy(Pell Bio-Med Technology)Anti-GD2 chimeric antigen receptor T cell therapy(Pell Bio-Med Technology)CAR-TNeoplasms Nervous System DiseasesDisialoganglioside GD2 inhibitors Immunologic cytotoxicity T lymphocyte replacementsPell Bio-Med Technology Co., Ltd.PreclinicalAnti-GD2 chimeric antigen receptor T cell therapy(Pell Bio-Med Technology)
detail  >
Anti-GD2 CAR-T (National Cancer )Anti-GD2 CAR-T (National Cancer )Autologous CAR-TNeoplasms Immune System Diseases Hemic and Lymphatic Diseases Skin and Musculoskeletal Diseases Other DiseasesDisialoganglioside GD2 inhibitorsNational Cancer InstitutePhase 1Anti-GD2 CAR-T (National Cancer )
detail  >
MB-CART GD2-IL18MB-CART GD2-IL18CAR-TNeoplasms Nervous System Diseases Other DiseasesDisialoganglioside GD2 inhibitorsMiltenyi Biomedicine GmbHMiltenyi Biomedicine GmbHPreclinicalMB-CART GD2-IL18
detail  >
Total 92 data
1
2
3
4
5
6
...
9
10